Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Molecular Imaging and Biology
Published in: Molecular Imaging and Biology 2/2013

01-04-2013 | Research Article

An In Vivo Evaluation of Cerebral Cortical Amyloid with [18F]Flutemetamol Using Positron Emission Tomography Compared with Parietal Biopsy Samples in Living Normal Pressure Hydrocephalus Patients

Authors: Dean F. Wong, Abhay R. Moghekar, Daniele Rigamonti, James R. Brašić, Olivier Rousset, William Willis, Chris Buckley, Adrian Smith, Beril Gok, Paul Sherwin, Igor D. Grachev

Published in: Molecular Imaging and Biology | Issue 2/2013

Login to get access

Abstract

Purpose

The primary objectives of this study were to assess the safety of [18F]flutemetamol injection and determine the level of association between the quantitative estimates of brain uptake of [18F]flutemetamol and the quantitative immunohistochemical (IHC) estimates of amyloid levels in cerebral cortex biopsies obtained during shunt placement in patients with normal pressure hydrocephalus (NPH).

Procedures

Parietal lobe biopsies were obtained from 12 subjects (mean (SD), 71 (8.1) years), during shunt placement for NPH. Shunt procedures and biopsies were performed within 8 weeks after the positron emission tomography (PET) imaging, and followed by a computed tomography scan.
The quantitative estimates of the brain uptake of [18F]flutemetamol (standard uptake value ratios (SUVRs)) from the biopsy site, contralateral to the biopsy site, and composite were made from the analysis of PET images. The quantitative IHC levels of amyloid load were estimated using a monoclonal antiamyloid β antibody, 4 G8 (in percent area), as the standard of truth (N = 8, of which 5 had full histopathology staining). The primary analysis determined the level of association between the SUVR (with cerebellum as the reference region) from the biopsy site, and the level of amyloid was determined from IHC estimates of amyloid in the biopsy sample.

Results

[18F]Flutemetamol injection was found to be well tolerated. The biopsied area well represented the amyloid deposition throughout the cortex in this small sample. The biopsy site SUVR was significantly correlated with the biopsy specimen amyloid β level (expressed as percent of biopsy specimen area staining with 4 G8). The full model was significant (p = 0.0174). In the secondary efficacy analyses, contralateral (to biopsy site) and composite SUVR values correlated significantly with the percent of biopsy specimen staining for amyloid β based on 4 G8. Blinded visual [18F]flutemetamol image interpretations showed a sensitivity of 100 % and a specificity of 100 % with pathology reads staining for amyloid plaque with Bielschowsky and thioflavin S and overall pathology read. The results of the blinded reader agreement for [18F]flutemetamol PET showed full agreement among three readers.

Conclusions

PET imaging of NPH patients following the administration of [18F]flutemetamol injection was highly correlated with the presence of fibrillar amyloid β in subsequent cortical biopsy samples in this small sample. Administration of [18F]flutemetamol injection was well tolerated.
Literature
1.
Chong MS, Sahadevan S (2005) Preclinical Alzheimer's disease: diagnosis and prediction of progression. Lancet Neurol 4:576–579PubMedCrossRef
2.
Grober E, Dickson D, Sliwinski MJ et al (1999) Memory and mental status correlates of modified Braak staging. Neurobiol Aging 20:573–579PubMedCrossRef
3.
Braak H, Braak E (1991) Neuropathological staging of Alzheimer's disease. Acta Neuropathol (Berl) 82:239–259CrossRef
4.
Gómez-Isla T, Hollister R, West H et al (1997) Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol 41:17–24PubMedCrossRef
5.
Arriagada PV, Growdon JH, Hedley-Whyte ET et al (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42:631–639PubMedCrossRef
6.
Cotran RS, Kumar V, Robbins SL (1989) Alzheimer's disease in: the nervous system. In: Cotran RS, Kumar V, Robbins SL (eds) Robbins pathologic basis of disease. 4th Edn. chapter 29. Saunders, Philadelphia. pp 1427–1429.
7.
Vallet PG, Guntern R, Hof PR (1992) A comparative study of histological and immunohistochemical methods for neurofibrillary tangles and senile plaques in Alzheimer's disease. Acta Neuropahol 83(2):170–178CrossRef
8.
DeGrado TR, Turkington TG, Williams JJ et al (1994) Performance characteristics of a whole-body PET scanner. J Nucl Med 35(8):1398–1406PubMed
9.
Yamamoto T, Hirano A (1986) A comparative study of modified Bielschowsky, Bodian and thioflavin S stains on Alzheimer's neurofibrillary tangles. Neuropathol Appl Neurobiol 12:3–9PubMedCrossRef
10.
Mirra SS, Heyman A, McKeel D et al (1991) The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41(4):479–486PubMedCrossRef
11.
Jack CR Jr, Lowe VJ, Senjem ML et al (2008) 11 C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 131:665–680PubMedCrossRef
12.
Jack CR Jr, Wiste HJ, Vemuri P et al (2010) Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain 133(11):3336–3348PubMedCrossRef
13.
Raji CA, Backer JT, Nicholas D et al (2008) Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer's disease with Pittsburgh compound B. J Neurosci Methods 172:277–282PubMedCrossRef
14.
Menon KV, Gomez D, Smith AM, et al. (2009) Impact of margin status on survival following pancreatoduodenectomy for cancer: the Leeds pathology protocol (LEEPP) 11(1): 18–24.
15.
Rossetti HC, Munro CC, Hynan LS et al (2010) The CERAD neuropsychologic battery total score and the progression of Alzheimer disease. Alzheimer Dis Assoc Disord 24(2):138–142PubMedCrossRef
16.
Leinonen V, Alafuzoff I, Aalto S et al (2008) Assessment of β-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh compound B. Arch Neurol 65(10):1304–1309PubMedCrossRef
17.
Wolk DA, Grachev ID, Buckley C et al (2011) Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Arch Neurol 68(11):1398–1403PubMedCrossRef
18.
Price JL, Morris JC (1999) Tangles and plaques in nondemented aging and preclinical Alzheimer's disease. Ann Neurol 45:358–368PubMedCrossRef
19.
Clark CM, Schneider JA, Bedell BJ, AV45–A07 Study Group et al (2011) Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 305(3):275–283PubMedCrossRef
20.
Wong DF, Rosenberg PB, Zhou Y, et al. (2010) In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir F 18). J Nucl Med. 2010 Jun;51(6):913–20. Erratum in: J Nucl Med. 2010 51(8):1327.
Metadata
Title
An In Vivo Evaluation of Cerebral Cortical Amyloid with [18F]Flutemetamol Using Positron Emission Tomography Compared with Parietal Biopsy Samples in Living Normal Pressure Hydrocephalus Patients
Authors
Dean F. Wong
Abhay R. Moghekar
Daniele Rigamonti
James R. Brašić
Olivier Rousset
William Willis
Chris Buckley
Adrian Smith
Beril Gok
Paul Sherwin
Igor D. Grachev
Publication date
01-04-2013
Publisher
Springer-Verlag
Published in
Molecular Imaging and Biology / Issue 2/2013
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI
https://doi.org/10.1007/s11307-012-0583-x

Other articles of this Issue 2/2013

Molecular Imaging and Biology 2/2013 Go to the issue

Research Article

Preclinical Evaluation of a Novel c-Met Inhibitor in a Gastric Cancer Xenograft Model Using Small Animal PET

Research Article

Electrophilic Addition of Chlorine Monofluoride for PET tracers

Research Article

Evaluation of [18F]Mefway Biodistribution and Dosimetry Based on Whole-Body PET Imaging of Mice

Research Article

Tumor-Specific Targeting With Modified Sindbis Viral Vectors: Evaluation with Optical Imaging and Positron Emission Tomography In Vivo

Research Article

Monitoring Therapy with MEK Inhibitor U0126 in a Novel Wilms Tumor Model in Wt1 Knockout Igf2 Transgenic Mice Using 18F-FDG PET with Dual-Contrast Enhanced CT and MRI: Early Metabolic Response Without Inhibition of Tumor Growth

Research Article

Peptide-Based Targeting of the Platelet-Derived Growth Factor Receptor Beta